ArticleRespiratory research2026
Desmoglein-2 dysregulation impairs epithelial barrier integrity in eosinophilic asthma.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- S100P mediates IL-13/ATF4-driven epithelial barrier dysfunction in eosinophilic asthma: a potential biomarker and therapeutic target.Journal of translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundEosinophilic asthma, affecting more than 50% of adult asthma patients, demonstrates airway inflammation severity directly correlated with eosinophil infiltration levels. While transepithelial eosinophil migration constitutes a pivotal step in airway inflammation pathogenesis, the regulatory mechanisms remain undefined. We aim to investigate how desmoglein-2 (DSG2), which is a key desmosomal cadherin mediating epithelial intercellular adhesion, regulates eosinophil transmigration across the bronchial epithelial barrier.
methodsDSG2 protein levels were measured by ELISA in asthma patients’ and healthy volunteers’ serum. In vitro, a lower level of DSG2 in bronchial cells weakened barrier integrity, boosting eosinophil migration. To further investigate the role of DSG2 in eosinophilic asthma, in vivo mouse studies were conducted. These studies employed an adeno-associated virus to modulate DSG2 expression (either downregulation or upregulation) or utilized exogenous supplementation with recombinant DSG2 protein, followed by assessment of their effects on ovalbumin (OVA)/house dust mite (HDM)-induced eosinophilic asthma.
resultsDSG2 was primarily expressed in human bronchial epithelial cells and was decreased in asthma patients compared to healthy individuals. The serum levels of DSG2 protein were significantly lower in asthmatic patients compared to healthy subjects. A negative correlation was observed between serum DSG2 protein levels and the count of peripheral blood eosinophils in asthma patients. Furthermore, Th2 cytokines interleukin-4 (IL-4) and interleukin-13 (IL-13) downregulated the expression of DSG2 protein. In bronchial epithelial cells, DSG2 protein played a crucial role in maintaining epithelial barrier function and cell adhesion. A reduction in its expression led to enhanced transepithelial migration of eosinophils in vitro. Consistent with these findings, a murine model of eosinophilic asthma exhibited decreased DSG2 expression and increased eosinophil infiltration in the airways. Notably, this eosinophil infiltration was exacerbated by the downregulation of DSG2. Critically, in both in vivo and in vitro experiments, overexpression of DSG2 in bronchial epithelial cells or exogenous addition of recombinant DSG2 protein partially reversed asthma-associated epithelial barrier impairment and alleviated eosinophilic airway inflammation.
conclusionWe elucidated the crucial role of DSG2 in bronchial epithelial cells during eosinophilic asthma development, focusing on its maintenance of desmosome structure and facilitation of eosinophil migration across the airway epithelium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.